Composite Indicator
Trend Spotter TM Hold

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy

Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 72517

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 46249

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 51601

Overall Average: 96% - Buy

Price Support Pivot Point Resistance

0.3000 0.1000 0.2800 0.4600

-------------------

New Gene Biomarkers Discovered for BPH (Benign Prostatic Hyperplasia)
Monday November 8, 8:40 am ET

SAVANNAH, GA--(MARKET WIRE)--Nov 8, 2004 -- Health Discovery Corporation (OTC BB:HDVY.OB - News) today announced the discovery of a new set of genetic biomarkers that are expected to lead to significant improvement in the diagnosis and treatment of Benign Prostatic Hyperplasia (BPH).

This set of newly discovered genetic biomarkers was able, with a high degree of accuracy, to separate BPH (Benign Prostatic Hyperplasia) from prostate cancer. These biomarkers were also shown to separate BPH from normal with a high degree of accuracy. This indicates that BPH is a disease with molecular characteristics of its own. This new discovery could be used to develop a non-invasive diagnostic test for BPH, which does not currently exist, as well as a completely new type of therapy for patients with this disease.

BPH is the enlargement of the prostate gland that occurs as men age and affects 33 million men worldwide. BPH occurs in approximately 25% of men over the age of 40, 50% of men over the age of 60, 80% of men over the age of 80, and 90% of men over the age of 85. The enlargement often leads to obstruction to the flow of urine flowing through the urethra that passes through the prostate gland. Of the 9 million cases of BPH in the United States, 2 million receive drug therapy treatment while an additional 7 million are "watchful waiters," men who are waiting for new treatments. BPH is a common condition, representing a $3 billion annual market in the United States alone.

Dr. Herbert Fritsche, Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center, stated, "This exciting new gene discovery could provide the vital information necessary to create a completely new drug to treat this extremely common disease. In addition, this new set of gene biomarkers, discovered by Health Discovery Corporation, could provide a diagnostic test used to evaluate patients undergoing treatment for BPH."

Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation, commented, "I am very proud of the accomplishments of our scientists in this new biomarker discovery and look forward to beginning the validation and commercialization efforts necessary to create what could be the worlds first non-invasive test for the diagnosis of BPH."

Detailed information on this discovery is available in the new Corporate Update Document just released and available on the company web page at www.healthdiscoverycorp.com.

Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(SM). Health Discovery Corporation was established to provide pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to produce more effective and cost effective diagnostic and drug discovery tools. Founded in September 2003, the Company is headquartered in Savannah, GA. For more information contact: Stephen D. Barnhill, M.D. of Health Discovery Corporation, +1-866-953-9031 or sbarnhill@healthdiscoverycorp.com.

-------------------------

New Gene Biomarkers Discovered for Prostate Cancer
Monday November 8, 8:00 am ET

SAVANNAH, GA--(MARKET WIRE)--Nov 8, 2004 -- Health Discovery Corporation (OTC BB:HDVY.OB - News) today announced the discovery of a new set of genetic biomarkers related to prostate cancer. This newly discovered gene set is expected to lead to considerable improvement in the diagnosis and treatment of clinically significant prostate cancer.

These biomarkers have been shown to accurately separate high-grade prostate cancers, the most malignant form of prostate cancer, from less malignant grades, with a high degree of accuracy. This ability would allow physicians to tailor prostate cancer treatment to a patient's specific type or grade of cancer resulting in significant cost savings by minimizing unnecessary or overly aggressive treatments as well as eliminating the adverse effects that invariably accompany unnecessary treatments.

Dr. Stamey, one of the world's leading prostate cancer experts and a Member of Health Discovery Corporation's Scientific Advisory Board, has been widely quoted in both scientific journals as well as in the national news media as stating, "We need to recognize that PSA is no longer a marker for prostate cancer. We urgently need to find a new marker for prostate cancer, and that marker must be proportional to how much cancer you have."

It has been shown that, financially, PSA is without equal among cancer markers. PSA sales, estimated at over $350 million annually, represents 40% of all annual cancer serum biomarker revenues. The reason for its large market share is that currently it is the only cancer biomarker that is being used for screening.

Dr. Herbert Fritsche, Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center, stated, "This impressive new gene discovery will give us access to a new set of biomarkers in advanced prostate cancer. We intend to use these findings to develop new diagnostic approaches for prostate cancer diagnosis and improve the clinical management of these patients."

Stephen D. Barnhill, M.D., Chairman and Chief Executive Officer of Health Discovery Corporation, commented, "We are extremely excited about this new biomarker discovery and will now begin the validation and commercialization efforts necessary to create what we believe could be a breakthrough in the diagnosis and treatment of clinically significant prostate cancer."

Detailed information on this discovery is available in the new Corporate Update Document just released and available on the company web page at www.healthdiscoverycorp.com.

----------------------------

Health Discovery Corporation Announces the Filing of Additional Patents for Newly Discovered Biomarkers in HIV Infection and New Biomarker Discovery Tools
Monday September 20, 8:01 am ET

SAVANNAH, GA--(MARKET WIRE)--Sep 20, 2004 -- Health Discovery Corporation (OTC BB:HDVY.OB - News) announced today that it has filed two additional United States patent applications on its fractal genomics modeling (FGM) technology in the identification of biomarkers for the development of diagnosis, prognosis and treatment of diseases. The first application, entitled "METHODS FOR IDENTIFYING BIOMARKERS USING FRACTAL GENOMICS MODELING," covers a "shotgun" approach in identifying biomarkers from a large dataset of gene expression values. The process is analogous to shotgun approaches to DNA sequencing, where a genetic network is shredded into component pieces and analyzed rather than a DNA sequence. The second application, entitled "BIOMARKERS IDENTIFIED USING FRACTAL GENOMICS MODELING," discloses and claims several biomarkers for human immunodeficiency virus (HIV) infection using the "shotgun" approach of fractal genomics modeling.

In addition, Health Discovery Corporation has submitted a United States and a Patent Cooperation Treaty (PCT) patent application entitled "METHOD FOR STUDYING CELLULAR CHRONOMICS AND CAUSAL RELATIONSHIPS OF GENES USING FRACTAL GENOMICS MODELING." The PCT application reserves the rights of Heath Discovery Corporation to file the patent application in more than 80 foreign countries who are members to the treaty. These applications are related to genomic analysis by Fractal Genomics Modeling (FGM) for developing single point gene models which can be used for studying cellular chronomics and causal relationship of genes within a genetic network. Using FGM, evidence of genes that govern fundamental clocking cycles in cell development and tissue differentiation of an organism can be produced. This clocking mechanism and the FGM methods used to produce its genetic components and function are described in these applications.

According to Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation, "These new patent applications, in conjunction with the other issued, pending, and provisional patent applications in our rapidly growing intellectual property portfolio, along with the recently signed worldwide exclusive licensing and joint ownership biomarker discovery contracts with world-renowned academic institutions such as MD Anderson Cancer Center, Stanford University and the University of Miami, as well as our establishment of a world-class team of scientists including, among others, Dr. Kary Mullis, winner of the Nobel Prize for his invention of PCR; Dr. Vladimir Vapnik, winner of the Humboldt Prize for his work on Statistical Learning Theory leading to the invention of the Support Vector Machine; Dr. Thomas Stamey, winner of the Ramon Guiteras award and considered to be the single most revered urologist and prostate cancer expert in the world; and Dr. Herbert Fritsche, one of the world's leading authorities on biomarker discoveries in cancer diagnostics, significantly strengthens Health Discovery Corporation's position as a leader in First Phase Biomarker Discovery." Dr. Barnhill continued, " I am extremely pleased with the accomplishments we have achieved in our first year as a biomarker discovery company and I am very excited about our future role in the rapidly growing commercial markets relating to diagnostic and drug discovery."

-------------------------------------

New Patent Expands Health Discovery Corporation's Intellectual Property Portfolio for Support Vector Machines
Tuesday September 7, 8:00 am ET

SAVANNAH, GA--(MARKET WIRE)--Sep 7, 2004 -- Health Discovery Corporation (OTC BB:HDVY.OB - News) announced today that its patent portfolio has been further strengthened with the issuance today of U.S. Patent No. 6,789,069 entitled "Method of Identifying Patterns in Biological Systems and Methods of Uses Thereof." This new patent covers the use of support vector machines (SVMs) for extracting useful information from large amounts of biological data. Technology covered by the patent's claims include methods for diagnosing and treating diseases by using SVMs to analyze gene expression data to identify groups of marker genes that exhibit strong correlation with the diseases. Specific examples of diseases include colon and breast cancer. The use of SVMs for analysis of gene expression data represents a significant improvement over existing analytical methods because it recognizes the interdependence of gene expression response among genes that are affected by the target disease.
"The granting of this patent by the United States Patent and Trademark Office adds great value to our patent portfolio of issued pioneer patents on support vector machines," stated Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation, "in addition to utilizing this patent protected technology for our own biomarker discovery efforts, we expect to generate significant near term revenue from licensing and royalty fees received from these very important patents which contain state-of-the-art technology used by diagnostic and pharmaceutical companies worldwide for identifying novel diagnostic tests and new drug targets."

Health Discovery Corporation (www.healthdiscoverycorp.com/) is a systems biology-oriented biomarker and pathway discovery company, which provides any and all aspects of "First Phase" biomarker discovery. This includes expert assessment of the clinical problem, determination of the clinical trial set-up, the proper selection and procurement of high-quality specimens for analysis, an analytical evaluation of the specimens through laboratory tests to produce the relevant accurate clinical data, and the mathematical evaluation of the data using state-of-the-art computational tools to produce an accurate identification of the important genes and proteins and the pathways in which they interact. Health Discovery Corporation was established to provide both pharmaceutical and diagnostic companies with a broad range of analytical and decision support solutions to accelerate effective diagnostic and drug discovery. Founded in September 2003, the Company has offices in Texas, Georgia and California. For more information, contact Robert S. Braswell IV of Health Discovery Corporation, +1-866-953-9031 or Info@healthdiscoverycorp.com.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

Contact:
Contact:
Robert S. Braswell IV
Health Discovery Corporation
+1-866-953-9031
Info@healthdiscoverycorp.com

------------------
'wid ma mind on ma money an' ma money on ma MIND!!!!!!!

Do Da Due!!!

RUFF!!!

SAVANNAH, GA--(MARKET WIRE)--Nov 15, 2004 -- Health Discovery Corporation (OTC BB:HDVY.OB - News) announced today that Dr. Stephen D. Barnhill, Chairman and CEO of the Company, will present the newly discovered biomarkers for Prostate Cancer, Benign Prostatic Hyperplasia (BPH), AIDS, and Leukemia at the upcoming NIBA conference on December 2-3, 2004 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.

National Investment Banking Association (NIBA) is a national trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. Since 1994, NIBA member firms have successfully completed some 800 equity offerings totaling approximately $8 billion in new capital for America's finest emerging growth companies.

Stephen D. Barnhill, M.D. commented, "I look forward to presenting our exciting new biomarker discoveries to this prestigious group of brokers, investment bankers and capital providers as part of our new effort to raise the awareness of the significance of our recent accomplishments."

Detailed information on this discovery is available in the new Corporate Update Document just released and available on the company web page at www.healthdiscoverycorp.com.

------------------
"When the strike of the hawk breaks the body of it's prey, it is because of timing"
The Art Of War - Sun Tzu

16-Nov-2004

Quarterly Report

Item 2. Management's Plan of Operations.
We have not realized any earned income since inception. However, we have entered into agreements with MD Anderson Cancer Center, Stanford University Medical Center and The University of Miami to perform analyses of clinical data using our computational technologies, which we expect will earn income after the identification, patent protecting and licensing of newly discovered biomarkers. We have secured both joint ownership rights and/or first options for worldwide exclusive rights to our discoveries in these contracts. After the close of the second quarter of 2004, we acquired the rights to a portfolio of patents that had initially been issued to Dr. Barnhill, our Chief Executive Officer, and to several members of our Scientific Advisory Board. Those patents, together with pending applications included in the portfolio, relate primarily to Support Vector Machines, which have applications in a wide variety of disciplines in which it is necessary to analyze complex data sets. We expect to be able to generate a stream of income by licensing the use of Support Vector Machines covered by the patents. We have been able to fund our operations though a private offering of our common stock under rules providing exemptions for such offerings and will continue to do so.

Our Technology.

Using our recently acquired technologies, which include Fractal Genomics, Support Vector Machines and other advanced computational techniques we intend to become the first company using these patent protected computational tools to perform "First-Phase Biomarker Discovery"; the total process of identifying a particular clinical medical problem to be solved and performing the entire process leading to the identification of the genes or proteins (called biomarkers), and the relationships among them (called pathways), that are relevant to the solution of the medical problem. This process will consist of an assessment of the clinical problem, the determination of the clinical trial set-up (the number of patients and what medical conditions they represent), the proper selection and procurement of high quality specimens for analysis, an analytical evaluation of the specimens through laboratory tests to produce the clinical data, the mathematical evaluation of the data using pattern recognition techniques and fractal geometry modeling to produce an accurate determination of the relevant genes and proteins and the manners in which they interact, and patent protecting these discoveries.

We intend to provide pharmaceutical and diagnostic companies with all aspects of "First-Phase Biomarker Discovery" diagnostic and drug discovery

Our Market

Developing and evaluating new drugs and medical therapies in less time and at lower cost is of enormous potential benefit for modern healthcare. Genuinely new products must pass a series of both in-vitro and in-vivo testing in order to demonstrate their safety and effectiveness for a specific clinical application. Historically, the endpoints of these trials were traditional ones tied to the actual disease being evaluated, such as a decrease in mortality or an objective/semi-objective decrease in clinical symptoms associated with the condition. In the last 10 to 15 years, there has been a move by the U.S. Food and Drug Administration (FDA) to incorporate other endpoints, including genes that are biomarkers for the existence or absence of a particular disease, which are nontraditional findings that are related to the presence or absence of disease.

Examples of successful application of biomarker data to therapeutic evaluation include the drugs Betaseron for use against multiple sclerosis and Herceptin in the treatment of breast cancer.

Our goal is to leverage the FDA's expedited approval process by producing more relevant and predictable biomarkers for drug discovery. By speeding up approval, new and better medicines and diagnostic markers can be developed for patients worldwide. Using our established relationships and signed discovery contracts with top US medical and cancer centers and our recently acquired fractal genomics computational technologies and support vector Machine technologies, our goal is to overcome the difficulties encountered with biomarker discovery and become the first company, to our knowledge, to perform the total process of "First-Phase Biomarker Discovery" by identifying a particular clinical problem to be solved and performing the entire process leading to the identification of the genes or proteins (called biomarkers), and the relationships among them (called pathways) that are relevant to the solution of the medical problem as described below. Once we discover these new biomarkers and pathways, we intend to immediately file patent applications to protect the discoveries such as with the patents filed for our Leukemia, AIDS, and Downs Syndrome discoveries.

These patent-protected biomarkers and pathways represent the products of our company. After our discovery is patent protected, the process of selling or licensing the newly discovered biomarkers and pathways will begin. The information will then be sold or licensed to diagnostic companies for development into new state-of-the-art diagnostic assays and the same information will be sold or licensed to pharmaceutical companies for further development into the next generation of therapeutic targets. Intellectual property is a key asset in diagnostic and drug discovery. Our products will be based on intellectual property, which includes the discovered biomarkers and pathways produced through our own internal research programs, as well as joint discovery efforts with academic institutions, diagnostic and pharmaceutical companies worldwide.

OUR CORPORATE STRATEGY

Our goal is to develop a product line of newly discovered biomarkers and pathways, which will include human genes, proteins and genetic proteonomic variations, as well as gene, protein and metabolite expression differences. In drug discovery, biomarkers can help elicit disease targets and pathways and validate mechanisms of drug action. They may also be pharmacodynamic indicators of drug activity, response and toxicity for use in clinical development.

We intend to provide pharmaceutical and diagnostic companies with all aspects of "First-Phase Biomarker Discovery" diagnostic and drug discovery from expert assessment of the clinical dilemma through proper selection and procurement of high quality specimens. We will then apply our proprietary analytical evaluation methods and state-of-the-art computational analysis to produce relevant and accurate clinical data, producing accurate biomarker and pathway discoveries, resulting in patent protection of our biomarker discoveries for future development.

We will provide any or all levels of "First-Phase Biomarker Discovery" biomarker discovery is based on the belief that in order to discover the most clinically relevant biomarkers, the computational component must begin at the inception of the clinical dilemma to be solved. This pathway includes several critical levels of decision-making all of which are part of our business strategy.

The first level of discovery is assessment of the clinical dilemma.

Is the desired biomarker or pathway to be identified related to early diagnosis, metastasis, treatment response or some other aspect of a given disease process? Based on the clinical question to be answered along with the incidence, prevalence and nature of the particular disease, we will establish a clinical study with the appropriate number of necessary specimens. We expect that these studies will provide statistically significant results once the biomarker and pathway discovery is completed.

The second level of discovery is the proper identification and procurement of the most relevant and professionally collected clinical specimens.

Based on the clinical dilemma to be solved, does the appropriate clinical trial determined by our team of exerts require blood, serum, aspirate fluid, tissue or some other clinically relevant specimen? Once the correct decision is made, we will procure the specimens necessary for the discovery from highly reputable institutions, like MD Anderson Cancer Center in Houston, Texas, where we believe proper collection and informed consent are completed under the strictest scientific protocol.

The third level of discovery is the analytical component.

The clinical specimens must then be analyzed and converted into relevant clinical data. l Our team of experts make the determine of which analytical method is appropriate for the most successful biomarker and pathway discovery. Our experts constantly monitor improvements in these techniques worldwide. The techniques we currently expect to use include mass spectroscopy, MALDI, SELDI, DNA methylation, gene chip analysis, 2-D Gel Electrophoresis, as well as other proprietary techniques developed by companies and academic institutions with which we have relationships.

The fourth level of discovery is the computational component.

The data generated from the analytical component must then be computationally analyzed for the discovery of new biomarkers, patterns among those biomarkers and causality pathways. Our team of experts decides which of the current leading computational algorithms, such as the fractal geometry modeling (FGM) techniques or support vector machine (SVM) techniques owned by the Company, are best suited to solve the particular clinical dilemma in question. The data is then computationally analyzed, and the new biomarkers and pathways are discovered and patent protected.

The Fifth Level Of Discovery is Patent Protect the Discovery.

Newly discovered biomarkers and pathways will be patented for future license to diagnostic companies for use in biomarker assays and to pharmaceutical companies for use in developing drug targets.

The Sixth Level Of Discovery Define the clinical validity and utility of discovered biomarkers.

Biomarkers uncovered through the four stages of discovery will be subsequently validated independently in larger, clinically relevant populations. Clinical validity of a biomarker is confirmed by its presence in the clinical condition in question and its ability to differentiate one disease state from another, or a diseased state from a healthy state. Markers validated by our processes may provide: vastly improved diagnostic capabilities; may identify potential therapeutic targets for pharmaceutical intervention (e.g. membrane signaling proteins and inhibitors); and markers suitable for monitoring disease progression following therapeutic intervention. Application of clinically validated biomarkers in such a manner will result in improved individual patient care and the advancement of the field of personalized medicine. This unique approach to biomarker discovery and its additional validation in relevant clinical samples advances the commercial potential of biomarkers uncovered by Health Discovery Corporation to diagnostic and therapeutic partners. Integration of the six levels of biomarker discovery should result in improved efficiencies in translation of this information into commercial and medically valuable products.

The goal of Health Discovery Corporation is to produce more relevant and predictable biomarkers for drug discovery so that new and better medicines and diagnostic markers can be developed for patients worldwide.

------------------
"When the strike of the hawk breaks the body of it's prey, it is because of timing"
The Art Of War - Sun Tzu

Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 107740

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 65040

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 53821

Overall Average: 88% - Buy

Price Support Pivot Point Resistance

0.2750 0.1783 0.2583 0.3383

http://quote.barchart.com/texadv.asp?sym=HDVY

------------------
"When the strike of the hawk breaks the body of it's prey, it is because of timing"
The Art Of War - Sun Tzu